Immunovant (IMVT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec12

Roivant Sciences Ltd. Acquires Immunovant Inc.

22:18

Goldman Sachs Analyst Maintains Hold Rating on Immunovant

21:22

Dec11

Immunovant Inc. Announces the Underwritten Public Offering Pricing of Its Common Stock

06:53

Nov11

Analyst Maintains Immunovant Buy Rating, Price Target at $50

09:16

Nov10

Immunovant released FY2026 Q2 earnings during market hours on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7285 (forecast USD -0.7179)

21:00

Immunovant released FY2026 Semi-Annual Earnings on November 10 During-Market (EST), actual revenue USD 0, actual EPS USD -1.4342

21:00

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2026 Q2 Earning Release (USD) Net Income -126.5 M, EPS -0.7285

Aug11

Earning Release(EST)

FY2026 Q1 Earning Release (USD) Net Income -120.61 M, EPS -0.7058

May29

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -106.45 M, EPS -0.6384

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change